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1Herpes zoster in hospitalized adults: The UCSF dermatology consult service experience
I. Ahronowitz and L. Fox. University of California, San Francisco, San Francisco, CA.
Background: Herpes zoster is commonly seen in immunocompromised adults and is
a frequent reason for inpatient dermatology consultations. We sought to characterize
the presentations of herpes zoster in hospitalized adults at our institution for whom
the dermatology service was consulted. Methods: We reviewed the UCSF inpatient
dermatology case log records and found a total of 1590 inpatient dermatology consults
between December 2009 and September 2013. Forty-six patients were identified with a
documented clinical diagnosis of herpes zoster. Results: Of these cases, 20 patients were
female and 26 male. The mean age of patients was 53.6 years. Immunosuppression was
documented in 31 (67%) of these patients (5 with HIV/AIDS, 9 with a hematologic
malignancy, 9 with solid organ transplants, 5 with autoimmune disease on immunosup-
pressive medication, and 3 with metastatic cancer). A direct fluorescent antigen (DFA)
assay from a skin swab was performed in 40 of the patients. Of these, 30 had a positive
DFA (75%), 6 had a negative DFA (15%), and 4 (10%) had an inconclusive result due to
insufficient cells in the submitted sample. Of the 6 patients who did not have a DFA
performed, 2 had viropathic changes seen on skin biopsy with positive VZV stains to
support the diagnosis. Twenty of the patients in our database (43%) were documented to
have disseminated zoster (defined as greater than 20 lesions outside of two contiguous
dermatomes), of which 7 were given a diagnosis of VZV meningoencephalitis (6 of these
had a positive VZV PCR on cerebrospinal fluid, and one had the diagnosis made based
on clinical symptoms without a lumbar puncture). No other non-cutaneous organ
involvement was reported. With regard to treatment, 17 patients were initially treated with
oral acyclovir, of which 4 went on to receive IV acyclovir. Twenty-seven patients received
IV acyclovir or ganciclovir as initial therapy, ranging from 1 to 14 days of treatment (many
transitioned to oral therapy once their lesions had crusted over). Only one patient received
no treatment. Average length of hospital stay was 11.6 days in the group without
disseminated herpes zoster, compared to 15.3 days in the subset whose disease was
disseminated. Conclusions: Our findings were in line with current knowledge that herpes
zoster is a considerable source of morbidity in hospitalized patients, particularly in those
with pre-existing immunocompromise, which represented the majority of zoster patients
for whom dermatology inpatient consultation was requested. Dissemination was common
in our patients and was associated with longer hospital stays. The most common non-
cutaneous focus of dissemination in our patients was the central nervous system. This is, to
our knowledge, the first study of hospitalized adults with zoster for whom dermatology
consultation was obtained.
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Early-onset mycosis fungoides among young African American women:
A single-institution study
Y. Balagula1, S. Dusza2, J. Zampella1, R. Sweren1 and G. Hinds1. 1Johns Hopkins School
of Medicine, Baltimore, MD and 2Memorial Sloan-Kettering Cancer, New York, NY.
Background: Mycosis Fungoides (MF) is the most common form of cutaneous T-cell
lymphoma and accounts for 54% of all CTCL cases. Few studies have specifically
addressed the incidence and stage of MF in relation to gender, age, and race. We
conducted a retrospective analysis of MF patients with specific attention to gender,
ethnicity and stage at presentation. Methods: A retrospective analysis of patients seen in
the Johns Hopkins Dermatology Clinics in Baltimore, MD, from 2000 to 2010 was
performed. Patients were identified by using International Classification of Diseases Ninth
Revision codes for MF and Sezary’s syndrome. Results: A total of 312 patients were
included in the study and the analysis was limited to 209 Caucasian and 103 African
American (AA) patients. AA patients presented at a significantly younger mean age (45 vs.
56) and were 2.6 times more likely to be diagnosed before the age of 40 compared to
Caucasians (OR¼ 2.6, 95% CI 1.5-4.5, po0.001). AAs were more likely to present with
stage IB (OR¼3.09, 95% CI 1.67-5.73, po0.001) and stage IIB (OR¼ 4.75, 95% CI 1.88-
11.98, po0.001) compared to stage IA. Analysis of young women (o40) demonstrated
that one is 10.6 times more likely to be AA than Caucasian at presentation with MF
(OR¼ 10.6, 95% CI 4.9-23.1, Po0.0001). Conclusion: Our results suggest that female
gender in African Americans is a risk factor for developing early-onset MF. Furthermore,
they suggest that this particular patient group may present with more extensive disease.
This apparent risk should be taken into consideration during clinical evaluation and
staging of patients and should inform treatment selection.
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Rituximab in the treatment of pemphigus: A retrospective review of 38 patients
S. Currimbhoy, V. Zhu and A. Pandya. University of Texas Southwestern Medical Center,
Dallas, TX.
Background: Pemphigus is an autoimmune blistering disease for which current treatment
is unsatisfactory. The most common treatment, oral corticosteroids, often fails to elicit
long term remission and has many adverse effects. We set out to evaluate the efficacy of
rituximab for the treatment of patients with pemphigus vulgaris and foliaceus.Methods: A
retrospective review of all patients with pemphigus treated with at least one cycle of
rituximab treatment and long-term follow up was performed. Outcomes included the
number of patients achieving partial (PR) complete remission (CR), time to remission,
mean prednisone dose required for disease control, adjuvant therapies, and relapse rates.
Results: 45 patients with pemphigus treated with rituximab were screened, of which 38 fit
the inclusion criteria. Mean follow-up time after the first cycle of Rituximab was 27 (±16)
months. 68% (26/38) of patients went into PR or CR after one cycle, with median time of 3
months (1–8 months). Most patients required additional cycles, leading to an overall
remission rate of 90%. Furthermore, the mean dose of prednisone was reduced from
34mg to 5mg three to six months after the first cycle. Conclusion: Rituximab is an
effective treatment for pemphigus, with an overall remission rate of 90%. Multiple cycles
may be needed to achieve a sustained remission.
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Palliative therapy for recalcitrant cutaneous T-cell lymphoma of the hands and feet
with low-dose HDR custom surface mold brachytherapy
Goddard1,2, N. LeBoeuf 1,2, D. O’Farrell1, R. Cormack1, J. Hansen1, T. Kupper 1,2 and
P. Devlin1,2. 1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA and
2Dana Farber Cancer Institute, Boston, MA.
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of malignancies of mature-
memory skin-resident T lymphocytes. The majority of patients with CTCL are treated with
skin directed therapies with or without systemic therapy. CTCL of the hands and feet can
be challenging to treat and is a cause of significant disability for patients. Although CTCL is
a highly radiosensitive tumor, the complex topography of hands and feet presents
challenges to achieving homogenous superficial dosing of traditional electron beam
therapy. In addition, traditional dosing of electron beam therapy may result in substantial
acute cutaneous toxicity. Recent reports demonstrate that low-dose (800 cGy) palliative
radiotherapy may be as effective as traditional higher dose regimens (2000–3600 cGy) in
CTCL. High-dose-rate (HDR) computer optimized surface applicator brachytherapy, the
administration of radiation through flexible catheters that can be secured within fully
customized molds, allows for control of the depth of radiation penetration over complex
curved surfaces. The goal of this study was to investigate the role of low-dose HDR
brachytherapy for CTCL lesions involving the hands and feet. Observation: This study
identified all patients at a single center treated with low-dose HDR brachytherapy for
CTCL lesions involving the hands and/or feet between January 2010 and December 2012.
The medical records of six patients with a total of eight acral CTCL lesions were reviewed.
All patients were treated in a university based, multidisciplinary cutaneous oncology
center. Rapid improvement and clinical clearance were observed in all treated lesions
with minimal to no acute cutaneous toxicity. Patients also reported subjective functional
improvement. Mean follow up was 15.8 months (Range 10.3-23.3 months). One patient
demonstrated recurrent disease of the palm after 12 months. The remainder of lesions
remain in clinical remission. No long term sequelae were observed. Conclusion: This
study demonstrates that low-dose HDR brachytherapy provides excellent palliation for
local control of acral CTCL lesions, offering homogenous, controlled dosing to complex
topographical sites. Minimal to no cutaneous toxicity was observed. Overall, patients
experienced improved cosmetic appearance and functionality as well as sustained lesion
recurrence free survival.
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5Epidemiological patterns in cutaneous non-tuberculous mycobacterial infections
P. Mattei, S. Chen, S. Nayak, and G. Hinds. Johns Hopkins Medical Institutions, Baltimore,
MD.
Cutaneous non-tuberculous mycobacterial infections have been increasing worldwide.
These infections may affect both healthy and immune-compromised patients. In addition,
they can be acquired in hospital settings through contaminated water, surgical devices,
and drugs which are dispensed in multi-use vials. Furthermore, patients may be exposed
in beauty salons through whirlpool footbaths, during natural disasters, and in occupations
such as fish handling. Perhaps because of their infrequency relative to other causes of
cutaneous infection, the diagnosis of these infections can present a clinical challenge. In
addition, they tend to be more difficult to culture and the morphology of the lesions they
produce may simulate other dermatologic conditions. There is a relative paucity of data
regarding cutaneous non-tuberculous mycobacterial infections. Treatment is generally
tailored to the species with some commonly encountered species being the rapid growing
Mycobacterium fortuitum, Mycobacterium chelonae, and Mycobacterium abscessus.
Clarithromycin has historically good activity against several non-tuberculous mycobac-
terial species, however, the presence of the naturally occurring erm gene in M. abscessus,
suggests a mechanism for macrolide resistance. Objective: To determine non-tuberculous
mycobacterial species and as well as epidemiologically related risk factors and
differences, we performed a retrospective chart review of patients with cutaneous non-
tuberculous mycobacterial infections seen at the Johns Hopkins Hospital and Johns
Hopkins Bayview outpatient dermatology and infectious disease clinics from 2011-2013.
Methods: The sex, date of birth, ethnic background, type of infection, age at time of
infection, location, treatment and exposure history were obtained from the microbiology
mycobacteria lab positive culture log book. Data was examined from January 2011
through November 2013. This data was recorded and analyzed. Results: A search of the
microbiology mycobacterial lab positive cultures log yielded 23 positive non-tuberculous
mycobacteria infections which involved the skin or subcutaneous tissues/lymphatics. The
mean age of infected individuals was 45 and the median age was 50. 15 of 23 of the
infected patients were male. In addition, 17 of 23 patients were white, 3 of 23 were black,
1 of 23 was Hispanic and 2 of 23 were listed as ‘‘other.’’ 6 of the 23 patients were on
chronic immunosuppressive therapy and 2 of 23 were HIV-positive. 10 of 23 cases
presented as cellulitis, 1 of 23 as panniculitis, 6 of 23 as abscess, 4 of 23 as lymphadenitis,
and 2 of 23 as ophthalmic infection. Infection sites involved multiple areas with 12 of 23
involving an extremity, 5 of 23 involving the head/neck, 3 of 23 involving the trunk, 2 of
23 involving the eyes, and 1 of 23 involving multiple visceral and cutaneous sites.
Exposure history was elicited from 18 of 23 records. Of these 18 records, 10 of 18
involved history of a surgical procedure and 4 of 18 involved exposure to salt water.
Interestingly, of the 10 cases with history of surgical procedure, 2 involved plastic surgery
in a foreign country (Dominican Republic and Peru). The remaining four case associations
were 1 exposure to livestock, 1 associated with HIV infection, 1 with travel to India, and 1
with periodontal/dental disease. Of the species identified, 3 were M. chelonae, 1 was M.
gordonae, 1 was M. fortuitum, 3 were M. marinum, 8 were M. abscessus, 5 were M.
avium/intracellulare (MAI), 1 was M. leprae and 1 is pending culture. Of note, all 3 cases
of M. marinum, were associated with salt water exposure, 4 of 5 cases of MAI presented as
lymphadenitis, and of the 3 pediatric cases identified, all 3 developed MAI lymphadenitis
presenting at 2 years of age. Limitations: Data was obtained from a single medical center
and may not be representative of other geographic locations. The incidence of cutaneous
non-tuberculous mycobacterial infection is rare and relatively few cases were identified.
Conclusions: Atypical mycobacterial infections are relatively rare. Surgical procedures
and salt water exposure are important risk factors for infection. Extremities were most
frequently affected in this series. Pediatric atypical mycobacterial infections are rare, but
when identified in this series, involved MAI lymphadenitis. In this series, whites and males
were more frequently affected. Further studies are needed to better characterize these
infections.
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Mildly and moderately dysplastic nevi: A retrospective analysis of re-excision utility
L. Strazzula, P. Vedak, M. Hoang, A. Sober, H. Tsao and D. Kroshinsky. Massachusetts
General Hospital, Boston, MA.
The natural history and clinical significance of mildly or moderately dysplastic nevi (DN)
is largely unknown. Currently, there is debate within the dermatology community
surrounding the management of DN, particularly surrounding the decision to re-excise
mildly or moderately DN with positive surgical margins during initial biopsy. Medical
dermatologists are often the first physicians to evaluate a patient with a clinically
suspicious nevus and are responsible for recommending further management. As the U.S.
healthcare climate more closely focuses on high quality and cost-effective medicine, the
cost-risk-benefit ratio of all clinical decisions will be further explored. In this study, we
sought to determine the utility of re-excising margin-positive mildly or moderately DN
based on histopathological yield. A retrospective review of all adult patients with biopsy-
proven dysplastic or malignant melanocytic lesions from 2010-2011 yielded 2,160
lesions. Of these, 1,809 were characterized as mildly or moderately dysplastic, and 765 of
these lesions had positive surgical margins during biopsy. Younger patients, larger lesions,
lesions on the head and neck, compound nevi, and nevi exhibiting congenital features
were more likely to have positive surgical margins whereas older patients, smaller lesions,
lesions on the lower extremity, and junctional nevi were more prevalent in the negative
margin group (po0.05). There was no statistically significant difference in margin
positivity when comparing shave removal versus punch biopsy techniques. 64.7% of
margin-positive mildly or moderately DN were subsequently re-excised. During re-
excision, 81.8% of specimens showed scar only with no residual melanocytes. One lesion
was diagnosed as a moderately DN during biopsy, and re-excision revealed a severely
atypical proliferation overlying a scar. Re-excision revealed no clinically significant
change in diagnosis in the remaining 99.8% of lesions. The results of this study are limited
by a short follow-up and therefore, do not comment on the long-term risk of nevus
recurrence or malignant transformation. Nonetheless, this is the largest study to date
examining the histopathological yield of re-excising mildly to moderately DN. Given that
only 18.2% of margin-positive lesions demonstrated residual melanocytes in re-excisional
specimens, these results suggest that re-excising DN for the purpose of lesion clearance
may not warranted. Further research evaluating the outcomes of clinically monitored DN
is necessary to further elucidate the long-term behavior of these clinically challenging
lesions.
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